Paul Celano, MD
Basic profilePaul Celano is an Oncology physician affiliated with Greater Baltimore Medical Center. OpenAlex indexes 41 publications with 5,866 citations (h-index 23).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
36 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck & Co.Program year20252 paymentsResearch$26,996
- PfizerProgram year20251 paymentResearch$3,000
- SpringWorks TherapeuticsProgram year202512 paymentsResearch$2,390
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
68.5%Integrin Receptor Antagonist37.6%Vedolizumab100%Part B, office-administered≥11 patientsPD-1 inhibitor30.1%Pembrolizumab100%Part B, office-administered≥15 patients+ 6 more classes in this area
Metabolism & gastrointestinal
14%Other antiemetics12.5%Fosaprepitant100%Part B, office-administered≥14 patientsSerotonin-3 Receptor Antagonist1.4%Palonosetron hcl100%Part B, office-administered≥21 patients+ 1 more class in this area
Musculoskeletal
13%RANK Ligand Inhibitor12.2%Denosumab100%Part B, office-administered≥20 patientsBisphosphonate0.8%Zoledronic acid100%Part B, office-administered≥85 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1990–1993 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1
Journal of Clinical Oncology
2026 - Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4
Journal of Clinical Oncology
2026 - Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours
Clinical and Translational Medicine
2026 - Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Susan Aucott, MD
Greater Baltimore Medical Center
Janet Sunness, MD
Greater Baltimore Medical Center
Joan Blomquist, MD
Greater Baltimore Medical Center
William Crawley, MD
Greater Baltimore Medical Center
Carl June, MD
University of Pennsylvania
Stuart Orkin, MD
Harvard Medical School
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”